Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ardea Biosciences has presented preclinical data that demonstrated the potent activity of the company's non-nucleoside reverse transcriptase inhibitor family of compounds against the human-immunodeficiency virus, the known causative agent of AIDS, including NNRTI-resistant strains.
Subscribe to our email newsletter
The data showed that Ardea’s lead NNRTI candidate, RDEA806, is a potent inhibitor of HIV, including the most common efavirenz resistant viruses. Oral dosing with RDEA806 achieved trough levels in humans that average at least 10-fold higher than the serum-adjusted EC50.
Barry Quart, president and CEO of Ardea, said: “This level of exposure over the concentration of drug needed to inhibit replication of the virus by 50% supports the potential for promising antiviral activity of our drug in HIV-infected patients who are naive to antiretroviral therapy.”